A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.

PubWeight™: 1.30‹?› | Rank: Top 10%

🔗 View Article (PMID 22307213)

Published in Am J Clin Oncol on April 01, 2013

Authors

Peter J Hosein1, Gilberto de Lima Lopes, Vitor H Pastorini, Christina Gomez, Jessica Macintyre, Gloria Zayas, Isildinha Reis, Alberto J Montero, Jaime R Merchan, Caio M Rocha Lima

Author Affiliations

1: *Department of Medicine, Division of Hematology/Oncology, Miller School of Medicine, University of Miami, Miami, FL †Department of Oncology, Johns Hopkins Singapore International Medical Center, Singapore, Republic of Singapore.

Associated clinical trials:

1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma | NCT04098081

Articles citing this

Update on taxane development: new analogs and new formulations. Drug Des Devel Ther (2012) 1.36

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer (2015) 1.29

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut (2013) 1.21

Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol (2014) 1.13

Deciphering the role of stroma in pancreatic cancer. Curr Opin Gastroenterol (2013) 1.03

Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. Carcinogenesis (2013) 1.01

Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol (2015) 1.00

Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther (2015) 0.97

New targeted therapies in pancreatic cancer. World J Gastroenterol (2015) 0.87

Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. Oncologist (2014) 0.87

Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. Exp Hematol Oncol (2015) 0.85

Update on current and potential nanoparticle cancer therapies. Curr Opin Oncol (2013) 0.85

Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. Ecancermedicalscience (2015) 0.84

A mathematical model for pancreatic cancer growth and treatments. J Theor Biol (2014) 0.82

Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World J Clin Oncol (2016) 0.80

Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease. BMC Cancer (2013) 0.79

DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer (2016) 0.79

Application of albumin-based nanoparticles in the management of cancer. J Mater Sci Mater Med (2015) 0.78

Pancreatic cancer: New hopes after first line treatment. World J Gastrointest Oncol (2016) 0.78

Pancreatic Cancer: Progress in Systemic Therapy. Gastrointest Tumors (2015) 0.77

Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma. J Gastrointest Oncol (2013) 0.76

Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. Gastrointest Cancer Res (2013) 0.75

Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Res (2013) 0.75

Genetic factors affecting patient responses to pancreatic cancer treatment. Ann Gastroenterol (2016) 0.75

Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. Ther Adv Med Oncol (2017) 0.75

Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer? J Gastrointest Oncol (2016) 0.75

Pancreatic ductal adenocarcinoma: metastatic disease. Clin Transl Oncol (2017) 0.75

Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials. Biomedicines (2016) 0.75

Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors. Langenbecks Arch Surg (2015) 0.75

Articles by these authors

Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33

Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03

A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol (2005) 1.80

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer (2012) 1.80

Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med (2012) 1.69

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol (2006) 1.60

Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol (2012) 1.57

Vulvar Langerhans cell histiocytosis: a case report and review of the literature. Gynecol Oncol (2003) 1.43

A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 1.41

Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma. Arch Surg (2010) 1.39

The roles of teaching hospitals, insurance status, and race/ethnicity in receipt of adjuvant therapy for regional-stage breast cancer in Florida. Am J Public Health (2005) 1.30

Treating breast cancer in the 21st century: emerging biological therapies. J Cancer (2013) 1.26

Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer (2013) 1.23

Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J Immunol (2009) 1.20

The effect of race/ethnicity and insurance in the administration of standard therapy for local breast cancer in Florida. Breast Cancer Res Treat (2005) 1.19

Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncol (2012) 1.16

Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res (2002) 1.15

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat (2010) 1.14

Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res (2009) 1.09

Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res (2005) 1.09

Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control (2009) 1.08

Re: Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ 2014;16(2):278-88. J Med Econ (2014) 1.07

Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med (2013) 1.05

Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer (2012) 1.05

EUS visualization and direct celiac ganglia neurolysis predicts better pain relief in patients with pancreatic malignancy (with video). Gastrointest Endosc (2011) 1.02

Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther (2003) 1.02

Upper gastrointestinal tumors: current status and future perspectives. Expert Rev Anticancer Ther (2008) 1.01

Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas. Breast Cancer Res Treat (2011) 1.00

Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics (2014) 0.98

Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters. Cancer Chemother Pharmacol (2012) 0.97

Adjuvant and preoperative therapy for localized gastric cancer. Gastrointest Cancer Res (2007) 0.97

5-fluorouracil-induced coronary vasospasm. Cancer Control (2004) 0.96

Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol Immunother (2007) 0.95

Utility of positron emission tomography scans in mantle cell lymphoma. Am J Hematol (2011) 0.95

Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKβ leading to autophagy. Biochem Pharmacol (2013) 0.94

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. Lung Cancer (2011) 0.93

Accelerated partial breast irradiation is safe and effective using intensity-modulated radiation therapy in selected early-stage breast cancer. Int J Radiat Oncol Biol Phys (2011) 0.92

Long-term fruit and vegetable change in worksites: Seattle 5 a Day follow-up. Am J Health Behav (2010) 0.92

A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer. Clin Breast Cancer (2008) 0.92

Successful treatment of anal gland adenocarcinoma with combined modality therapy. Gastrointest Cancer Res (2012) 0.90

A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin Cancer Res (2010) 0.90

Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors. Gastrointest Cancer Res (2008) 0.88

Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control (2003) 0.88

Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer. Clin Breast Cancer (2005) 0.86

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev (2011) 0.86

Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells. Mol Carcinog (2011) 0.86

Interferon-gamma suppresses cyclooxygenase-2 promoter activity by inhibiting C-Jun and C/EBPbeta binding. Arterioscler Thromb Vasc Biol (2007) 0.86

Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Ther Clin Risk Manag (2008) 0.85

Salivary markers and risk factor data: a multivariate modeling approach for head and neck squamous cell carcinoma detection. Cancer Biomark (2011) 0.85

Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice--a longitudinal analysis. Support Care Cancer (2014) 0.85

A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer. Breast Cancer Res Treat (2012) 0.84

Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. Cancer Biol Ther (2007) 0.84

Medicare reimbursement changes and the practice of oncology: understanding of the past is a key to the future. J Oncol Pract (2011) 0.83

Role of patient race/ethnicity, insurance and age on Pap smear compliance across ten community health centers in Florida. Ethn Dis (2010) 0.83

The glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress. Free Radic Biol Med (2012) 0.82

Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control (2003) 0.82

Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. Clin Breast Cancer (2004) 0.82

A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol (2014) 0.82

A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma. Jpn J Clin Oncol (2011) 0.81

Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer. Anticancer Res (2014) 0.81

Antiangiogenic property of human thrombin. Microvasc Res (2003) 0.81

Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Am J Clin Oncol (2012) 0.81

A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors. Cancer (2012) 0.81

Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma. Head Neck (2011) 0.81

Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat (2014) 0.81

Achyranthes aspera (Apamarg) leaf extract inhibits human pancreatic tumor growth in athymic mice by apoptosis. J Ethnopharmacol (2012) 0.80

Clinical outcomes in breast cancer patients with HIV/AIDS: a retrospective study. Breast Cancer Res Treat (2015) 0.79

Role of plasminogen activator inhibitor-1 in urokinase's paradoxical in vivo tumor suppressing or promoting effects. Mol Cancer Res (2012) 0.79

Emerging cell-cycle inhibitors for pancreatic cancer therapy. Expert Opin Emerg Drugs (2012) 0.79

Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab. J Clin Oncol (2007) 0.79

Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer (2007) 0.78

Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Oncology (Williston Park) (2003) 0.78

Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck. Head Neck (2014) 0.78

Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer (2007) 0.78

Cost-benefit of the 21-gene breast cancer recurrence score assay for patients in Singapore. Breast J (2013) 0.78

Pharmacoeconomic issues in head and neck oncology. Curr Opin Oncol (2013) 0.78

Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep (2012) 0.78

Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma. Med Oncol (2011) 0.78

A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer. Breast Cancer Res Treat (2013) 0.77

A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer. Breast Cancer Res Treat (2014) 0.76

A case of severe thrombotic thrombocytopenic purpura with concomitant Legionella pneumonia: review of pathogenesis and treatment. Am J Ther (2011) 0.76

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest New Drugs (2014) 0.76

Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory. Am J Cancer Res (2011) 0.76

Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma. J Neurooncol (2004) 0.76

In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer. Breast Cancer Res Treat (2014) 0.76

Oxaliplatin induced disseminated intravascular coagulation: A case report and review of literature. World J Gastrointest Oncol (2012) 0.75

Leveraging combinatorial chemotherapy to improve outcomes in patients with pancreatic cancer. Cancer Biol Ther (2010) 0.75

Locoregional outcomes in clinical stage IIB breast cancer after neoadjuvant therapy and mastectomy with or without radiation. Medicine (Baltimore) (2014) 0.75

What patients and providers should understand about economic evaluations in oncology. J Oncol Pract (2012) 0.75

Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L. Immunol Res (2013) 0.75

Patient with synchronous low grade leiomyosarcoma of the thigh, primary pancreatic neuroendocrine tumor, and lung metastases: Why biopsy of metastases should be the standard. J Gastrointest Oncol (2011) 0.75

Sustained response to FOLFOX and Bevacizumab in metastatic bronchial carcinoid - A case report and review of the literature. J Gastrointest Oncol (2011) 0.75

Enzyme-Driven Chemo-and Radiation-Therapy with 12 Pyrimidine Nucleoside Analogs Not Yet in the Clinic. Anticancer Agents Med Chem (2016) 0.75

Flow immunocytochemistry of marker expression in cells from body cavity fluids. Cytometry A (2010) 0.75

Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. Cancer Biol Ther (2008) 0.75